TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04038502

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Chemotherapy FDA approved drug used to treat: ovarian, lung, head and neck cancers. It is sometimes used in combination with other medications or off-label use to treat other metastatic cancers.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Chemotherapy FDA approved drug used to treat: ovarian, lung, head and neck cancers. It is sometimes used in combination with other medications or off-label use to treat other metastatic cancers.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olaparib
Description: Olaparib is a targeted therapy drug that is used for mCRPC and is approved by the FDA for this use.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olaparib
Description: Olaparib is a targeted therapy drug that is used for mCRPC and is approved by the FDA for this use.
Study: NCT02211794

Intervention type: OTHER
Intervention: data collection
Study: NCT02429635

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: My exercise
Description: Health Screening I and II Questionnaires on health and lifestyle, physiological test of fitness, physiological health tests and blood profile - compiled in a health profile report. Individual guidance and advice from professional health advisor.~Team-workshop I and II A 2 hours' workshop lead and facilitated by a trained and professional health advisor. It consists of short talks on exercise and health, and on health behavior change and motivation in addition to work with self-reflection and discussion tasks. Competence, support and advice during 2. workshop.~Exercise groups Small groups with similar exercise level and ambitions who support each other in their efforts to establish new exercise habits according to their individual exercise plan

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: My exercise
Description: Health Screening I and II Questionnaires on health and lifestyle, physiological test of fitness, physiological health tests and blood profile - compiled in a health profile report. Individual guidance and advice from professional health advisor.~Team-workshop I and II A 2 hours' workshop lead and facilitated by a trained and professional health advisor. It consists of short talks on exercise and health, and on health behavior change and motivation in addition to work with self-reflection and discussion tasks. Competence, support and advice during 2. workshop.~Exercise groups Small groups with similar exercise level and ambitions who support each other in their efforts to establish new exercise habits according to their individual exercise plan
Study: NCT05010603

Intervention type: GENETIC
Intervention: Blood Draw
Description: Collection of blood samples for genetic testing

Intervention type: GENETIC
Intervention: Blood Draw
Description: Collection of blood samples for genetic testing
Study: NCT04190459

Intervention type: PROCEDURE
Intervention: LSG
Description: Bariatric surgery

Intervention type: PROCEDURE
Intervention: LRYGB
Description: Bariatric surgery
Study: NCT06524102

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Activated Cell Sorting
Description: The MACS® ART Annexin V System has been designed for the in vitro elimination of apoptotic human spermatozoa in fresh, cryopreserved or otherwise manipulated semen samples. Samples processed by this technique can be subsequently used in any assisted reproduction procedure.~Annexin V recognizes externalized phosphatidylserine (ePS) on the plasma membrane of apoptotic spermatozoa. Depletion of the altered sperm begins with magnetic tagging of the sperm. The system selectively retains unwanted sperm by utilizing the natural ability of annexin V to recognize the ePS on the plasma membrane of the altered sperm, because annexin V is conjugated to metal microspheres. The labeled cells pass through a separation column in a fixed magnetic field. Unwanted (altered) spermatozoa are selectively retained in the separation column. Unlabeled spermatozoa pass through the column where they are collected for later use.
Study: NCT01431612

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esmolol administration
Description: 50 µg/kg/min of the ß1-receptor-blocker esmolol was infused intravenous over 3 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine infusion
Description: 0.01 µg/kg/min of the alpha-1-adrenergic receptor agonist phenylephrine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lactated Ringer´s solution
Description: Intravenous Infusion of 10 ml/h lactated Ringer's solution that contained no drug
Study: NCT02203734

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Moderate Pressure Massage
Description: The massage therapy will begin with the mother in a side-lying position, with pillows positioned behind her back and between her legs for support. The massage is given in the following sequence and repeated twice (10 minutes on each side for 20 minutes total) on the following areas: 1) Head and neck: 2) Back: 3) Arms: and 4) Legs. The effective moderate pressure (measured by a pressure meter) is 8 db or a slight indentation in the skin.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Light Pressure Massage
Description: The light pressure massage group will receive light pressure massage in contrast to the treatment group who will receive moderate pressure massage. As with moderate pressure massage, each session will begin with the mother in a side-lying position, with pillows positioned behind her back and between her legs for support. The massage is given in the following sequence and repeated twice (10 minutes on each side for 20 minutes total) on the following areas: 1) Head and neck: 2) Back: 3) Arms: and 4) Legs.
Study: NCT05759507

Intervention type: PROCEDURE
Intervention: abdominal surgery
Study: NCT04686461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nigella sativa seeds extract containing ointment intervention
Description: Nigella sativa seeds extract containing ointment Nigella sativa seed extract, bee wax, white petrolatum, stearyl alcohol
Study: NCT00980187

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide
Description: orally, 25 mg, once a day, with Quinapril 10-40 mg, 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indapamide
Description: 1.5 mg SR, orally, once a day,with Quinapril 10-40 mg, 6 months
Study: NCT01413035

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSC
Description: 1.0E+6 MSC/kg, IV drop in Day 0 and repeat to apply in Day 90 if the effect of MSC is better.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSC
Description: 1.0E+6 MSC/kg, IV drop in Day 0 and repeat to apply in Day 90 if the effect of MSC is better.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSC
Description: 1.0E+6 MSC/kg, IV drop in Day 0 and repeat to apply in Day 90 if the effect of MSC is better.
Study: NCT03167892

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oral screen
Description: Oral screen training three times per day with an effective training time of 1.5 minutes, for 3 mo
Study: NCT00582361

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Wound Dressing
Description: Group A patients will have a standard dressing applied following initial treatment of their open fracture. They will return to the operating room approximately 48 hours following the initial trauma, and approximately every 48 hours thereafter, for irrigation and debridement and concomitant wound cultures (qualitative and quantitative) until such time as the wound is judged by the surgeon to be ready for either delayed primary closure or flap/skin graft coverage.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VAC
Description: Group B patients will have a Vacuum Assisted Closure (VAC) device applied following initial treatment of their open fracture. They will return to the operating room approximately 48 hours following the initial trauma, and approximately every 48 hours thereafter, for irrigation and debridement and concomitant wound cultures (qualitative and quantitative) until such time as the wound is judged by the surgeon to be ready for either delayed primary closure or flap/skin graft coverage.
Study: NCT03718130

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Hantaan/Puumala (HTNV/PUUV) virus vaccines - Using the TriGrid Delivery System (TDS) for Intradermal Delivery (ID)
Description: The HTNV and PUUV vaccines will be administered using the ID TriGrid™ Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroportation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Hantaan/Puumala (HTNV/PUUV virus vaccines - Using the TriGrid Delivery System (TDS) for Intramusular Delivery (IM)
Description: The HTNV and PUUV vaccines will be administered using the IM TriGrid™ Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroportation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.
Study: NCT05010603

Intervention type: GENETIC
Intervention: Blood Draw
Description: Collection of blood samples for genetic testing

Intervention type: OTHER
Intervention: Late Onset Alzheimer's Disease (LOAD) Neuropsychological Battery Test
Description: Memory Test

Intervention type: OTHER
Intervention: Late Onset Alzheimer's Disease (LOAD) Neuropsychological Battery Test
Description: Memory Test

Intervention type: OTHER
Intervention: Late Onset Alzheimer's Disease (LOAD) Neuropsychological Battery Test
Description: Memory Test
Study: NCT01054508

Intervention type: DRUG
Group type: OTHER
Intervention: nicotinic acid/laropiprant
Description: Nicotinic acid/laropiprant (1g/20mg) daily for 4 weeks, then nicotinic acid/laropiprant (2g/40mg) daily for 8 weeks.

Intervention type: DRUG
Group type: OTHER
Intervention: nicotinic acid/laropiprant
Description: Nicotinic acid/laropiprant (1g/20mg) daily for 4 weeks, then nicotinic acid/laropiprant (2g/40mg) daily for 8 weeks.
Study: NCT04483700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib
Description: Tablets administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib
Description: Tablets administered orally once daily
Study: NCT04949347

Intervention type: BIOLOGICAL
Intervention: glaucoma drainage device implantation
Description: Glaucoma drainage device implantation, a 350 mm2 Baerveldt (BG 101-350) GDD (Johnson and Johnson, Santa Ana, CA, USA) was performed using glycerin-preserved, human-donor, corneoscleral tissue ( the remaining from a heterologous, human-donor corneal button, obtained from the International Eye Bank of Thailand, after a clear corneal graft had been used for penetrating keratoplasty.) The tissue had been preserved in glycerin using the sterile technique and kept in a medical refrigerator for no longer than 6 months.
Study: NCT04783831

Intervention type: DEVICE
Intervention: Biodegradable stent
Description: Biodegradable stent (polymeric prostheses) is placed from the pancreatic duct to the jejunum. Duct-to-mucosa end-to-side anastomosis is performed for the pancreaticojejunal anastomosis.

Intervention type: DEVICE
Intervention: Biodegradable stent
Description: Biodegradable stent (polymeric prostheses) is placed from the pancreatic duct to the jejunum. Duct-to-mucosa end-to-side anastomosis is performed for the pancreaticojejunal anastomosis.
Study: NCT01856777

Intervention type: DEVICE
Group type: OTHER
Intervention: Semi-quantitative panel test

Intervention type: DEVICE
Group type: OTHER
Intervention: High sensitivity urine pregnancy test
Study: NCT03990831

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Functional near-infrared spectroscopy (fNIRS)
Description: Functional near-infrared spectroscopy (fNIRS) measurement
Study: NCT02869854

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: Mindfulness course during 8 weeks with 20 minutes mindfulness exercise each day

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness
Description: Mindfulness course during 8 weeks with 20 minutes mindfulness exercise each day

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PAP
Description: Physical Activity on Prescription, after 3 months a new prescription

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PAP
Description: Physical Activity on Prescription, after 3 months a new prescription
Study: NCT02813629

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS plus PES
Description: transcranial direct current stimulation (tDCS) uses a pair of electrodes and sponges soaked in saline solution placed over specific regions of the head to polarize neurons and produce changes in resting membrane potentials. This changes may increase or decrease neuronal excitability and produce diverse clinical effects, including analgesia.~PES uses also a pair of electrodes over specific regions of the body to promote neuronal action potentials in peripheral nerves. PES over motor threshold increases cortical excitability, and at the sensory threshold decreases excitability.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS plus PES
Description: transcranial direct current stimulation (tDCS) uses a pair of electrodes and sponges soaked in saline solution placed over specific regions of the head to polarize neurons and produce changes in resting membrane potentials. This changes may increase or decrease neuronal excitability and produce diverse clinical effects, including analgesia.~PES uses also a pair of electrodes over specific regions of the body to promote neuronal action potentials in peripheral nerves. PES over motor threshold increases cortical excitability, and at the sensory threshold decreases excitability.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS plus PES
Description: transcranial direct current stimulation (tDCS) uses a pair of electrodes and sponges soaked in saline solution placed over specific regions of the head to polarize neurons and produce changes in resting membrane potentials. This changes may increase or decrease neuronal excitability and produce diverse clinical effects, including analgesia.~PES uses also a pair of electrodes over specific regions of the body to promote neuronal action potentials in peripheral nerves. PES over motor threshold increases cortical excitability, and at the sensory threshold decreases excitability.
Study: NCT03253679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adavosertib
Description: Given PO
Study: NCT00006016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given transarterially (chemoembolization)
Study: NCT02813629

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS plus PES
Description: transcranial direct current stimulation (tDCS) uses a pair of electrodes and sponges soaked in saline solution placed over specific regions of the head to polarize neurons and produce changes in resting membrane potentials. This changes may increase or decrease neuronal excitability and produce diverse clinical effects, including analgesia.~PES uses also a pair of electrodes over specific regions of the body to promote neuronal action potentials in peripheral nerves. PES over motor threshold increases cortical excitability, and at the sensory threshold decreases excitability.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS plus PES
Description: transcranial direct current stimulation (tDCS) uses a pair of electrodes and sponges soaked in saline solution placed over specific regions of the head to polarize neurons and produce changes in resting membrane potentials. This changes may increase or decrease neuronal excitability and produce diverse clinical effects, including analgesia.~PES uses also a pair of electrodes over specific regions of the body to promote neuronal action potentials in peripheral nerves. PES over motor threshold increases cortical excitability, and at the sensory threshold decreases excitability.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS plus PES
Description: transcranial direct current stimulation (tDCS) uses a pair of electrodes and sponges soaked in saline solution placed over specific regions of the head to polarize neurons and produce changes in resting membrane potentials. This changes may increase or decrease neuronal excitability and produce diverse clinical effects, including analgesia.~PES uses also a pair of electrodes over specific regions of the body to promote neuronal action potentials in peripheral nerves. PES over motor threshold increases cortical excitability, and at the sensory threshold decreases excitability.
Study: NCT00006016

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT04567069

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC vaccine
Description: Blood samples will be collected twice, 60-120ml/ time. The 1st collection will occur 5 days before the 1st DC vaccine injection, the 2nd collection will occur 15 days after the 1st injection.~Six subcutaneous(ih) injections of DC vaccine will be given at days 1, 8, 15, 21, 28, 35; 1-3×106 cells/time.~Injection site: inguinal lymph nodes.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC vaccine
Description: Blood samples will be collected twice, 60-120ml/ time. The 1st collection will occur 5 days before the 1st DC vaccine injection, the 2nd collection will occur 15 days after the 1st injection.~Six subcutaneous(ih) injections of DC vaccine will be given at days 1, 8, 15, 21, 28, 35; 1-3×106 cells/time.~Injection site: inguinal lymph nodes.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC vaccine
Description: Blood samples will be collected twice, 60-120ml/ time. The 1st collection will occur 5 days before the 1st DC vaccine injection, the 2nd collection will occur 15 days after the 1st injection.~Six subcutaneous(ih) injections of DC vaccine will be given at days 1, 8, 15, 21, 28, 35; 1-3×106 cells/time.~Injection site: inguinal lymph nodes.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CTL
Description: Four intravenous (iv) drip injections of CTL will be given at days 7, 9, 27, 29; 1-2×109 cells/time.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab Injection
Description: The Sintilimab Injection (3mg/kg) will be administered by intravenous (iv) drip injection at days 0, 20。
Study: NCT03926286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FMP-30
Description: FMP-30 containing frozen human fecal microbiota administered as (3) units of FMP30 enema on Day 0 and Week1
Study: NCT00402857

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incredible Years Program
Description: The Incredible Years Program is a 10-week group parenting intervention. Parent training sessions will take place once per week for 10 weeks, and will last approximately 2 hours each. Sessions will focus on teaching positive parenting skills, such as appropriate play and use of praise and rewards, as well as limit-setting techniques, such as ignoring, allowing children to experience the natural consequences of their actions, and assigning time-outs.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Incredible Years Program
Description: The Incredible Years Program is a 10-week group parenting intervention. Parent training sessions will take place once per week for 10 weeks, and will last approximately 2 hours each. Sessions will focus on teaching positive parenting skills, such as appropriate play and use of praise and rewards, as well as limit-setting techniques, such as ignoring, allowing children to experience the natural consequences of their actions, and assigning time-outs.
Study: NCT00471055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.0125% Capsaicin gel CAPSIKA gel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00829738

Intervention type: DRUG
Intervention: Pantoprazole
Description: This was an observational study. Therefore, the physician decided about dosage according to individual needs (20 or 40 mg pantoprazole).
Study: NCT03467958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozanimod
Description: Specified dose on specified days
Study: NCT03642873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Humibid®
Description: Humibid® 1200 mg (single extended release) tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocodone Bitartrate
Description: Hydrocodone Bitartrate (3.33 mg q4h X 3)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Humibid® and Hydrocodone Bitartrate tablet
Description: Humibid® 1200 mg (single extended release) tablet and Hydrocodone bitartrate (3.33 mg q4h X 3)
Study: NCT03819985

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiation Therapy
Description: Undergo hypofractionated RT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT02433626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COTI2
Description: COTI-2 is a third generation thiosemicarbazone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COTI2
Description: COTI-2 is a third generation thiosemicarbazone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin is approved to treat a range of solid tumors and lymphomas.
Study: NCT00844844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eculizumab
Description: All patients received open-label eculizumab administered intravenously on the following dose schedule: Induction dose - 900 mg per week for four weeks and a dose of 1200 mg one week later; Maintenance dose - 1200 mg every two weeks. Patients who received plasma exchange or infusion during the eculizumab treatment period received a supplemental dose of 600 mg within one hour before plasma infusion or within one hour after the completion of each plasma exchange.
Study: NCT03905096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809
Description: Film coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809
Description: Film coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Film coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Film coated tablet
Study: NCT02512549

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary Rehabilitation
Study: NCT02560259

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: Physiotherapy

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Conservative treatment
Description: Conservative treatment